Carole Sable

Carole Sable

Director/Miembro de la Junta en BASILEA PHARMACEUTICA AG .

Fortuna: - $ al 31/05/2026

64 años
Health Technology
Consumer Services

Perfil

Carole A. Sable is currently an Independent Non-Executive Director at Basilea Pharmaceutica AG since 2023.
Former positions include Executive Director-Clinical Research at Merck & Co., Inc. from 1995 to 2007, Vice President at Merck & Co., Inc. from 2010 to 2013, Chief Medical Officer at Vitae Pharmaceuticals LLC in 2016, Assistant Professor at the University of Virginia from 1993 to 1995, Chief Medical Officer at SCYNEXIS, Inc. from 2014 to 2015, Chief Medical Officer at Novexel SA from 2009 to 2010, Head-Clinical Development at Antabio SAS from 2018 to 2021, and Chief Medical Officer at Revolution Medicines, Inc. from 2015 to 2016.
Education includes a doctorate from Thomas Jefferson University, a doctorate from Sidney Kimmel Medical College conferred in 1983, and an undergraduate degree from the University of Scranton.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
31/12/2025 0 ( -.--% ) - $ 31/05/2026

Cargos activos de Carole Sable

EmpresasCargoInicio
BASILEA PHARMACEUTICA AG Director/Miembro de la Junta 27/04/2023

Antiguos cargos conocidos de Carole Sable.

EmpresasCargoFin
Director Técnico/Científico/I+D 01/01/2021
VITAE PHARMACEUTICALS INC Director Técnico/Científico/I+D 01/11/2016
REVOLUTION MEDICINES, INC. Director Técnico/Científico/I+D 01/01/2016
SCYNEXIS, INC. Director Técnico/Científico/I+D 20/02/2015
MERCK & CO., INC. Corporate Officer/Principal 01/01/2013
Ver el detalle de la experiencia de Carole Sable.

Formación de Carole Sable.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

84

Relaciones de 1er grado

11

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas11

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN